Novel acetylcholinesterase inhibitor as increasing agent on rhythmic bladder contractions: SAR of 8-{3-[1-(3-fluorobenzyl)piperidin-4-yl]propanoyl}- 1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (TAK-802) and related compounds

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 6, 2005, Pages 1901-1911

  Ishichi, Yuji ^a   Sasaki, Mitsuru ^a   Setoh, Masaki ^a   Tsukamoto, Tetsuya ^a   Miwatashi, Seiji ^a   Nagabukuro, Hiroshi ^a   Okanishi, Satoshi ^a   Imai, Shigemitsu ^a   Saikawa, Reiko ^a   Doi, Takayuki ^a   Ishihara, Yuji ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Acetylcholinesterase inhibitor; Pyrrolos 3,2,1 ij quinolin 4 one; Rhythmic bladder contraction; TAK 802

Indexed keywords

2 [[4 [3 OXO 3 (4 OXO 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 8 YL)PROPYL]PIPERIDIN 1 YL]METHYL]BENZONITRILE; 3 (1 BENZYLPIPERIDIN 4 YL) 1 (2,3,4,5 TETRAHYDRO 1,4 BENZOXAZEPIN 7 YL)PROPAN 1 ONE; 3 (1 BENZYLPIPERIDIN 4 YL) 1 (2,3,4,5 TETRAHYDRO 1H 2 BENZAZEPIN 8 YL)PROPAN 1 ONE; 3 (1 BENZYLPIPERIDIN 4 YL) 1 (2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YL)PROPAN 1 ONE; 3 [[4 [3 OXO 3 (4 OXO 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 8 YL)PROPYL]PIPERIDIN 1 YL]METHYL]BENZONITRILE; 4 [[4 [3 OXO 3 (4 OXO 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 8 YL)PROPYL]PIPERIDIN 1 YL]METHYL]BENZONITRILE; 8 [3 (1 BENZYLPIPERIDIN 4 YL)PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 (1 BENZYLPIPERIDIN 4 YL)PROPANOYL] 5,6 DIHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 2(IH) ONE; 8 [3 [1 (2 CHLOROBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 [1 (2 HYDROXYBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 [1 (2 METHOXYBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 [1 (2 NITROBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 [1 (3 CHLOROBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 [1 (3 FLUOROBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 [1 (3 HYDROXYBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 [1 (3 METHOXYBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 [1 (3 NITROBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 [1 (4 CHLOROBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 [1 (4 FLUOROBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 [1 (4 HYDROXYBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 [1 (4 METHOXYBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [3 [1 (4 NITROBENZYL)PIPERIDIN 4 YL]PROPANOYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8,3 [1 (2 FLUOROBENZYL)PIPERIDIN 4 YL]PROPANOYL 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 9 [3 (1 BENZYLPIPERIDIN 4 YL)PROPANOYL] 1,2,6,7 TETRAHYDROAZEPINO[3,2,1 HI]INDOL 4(5H) ONE; 9 [3 (1 BENZYLPIPERIDIN 4 YL)PROPANOYL] 2,3,6,7 TETRAHYDRO 1H,5H PYRIDO[3,2,1 IJ]QUINOLIN 5 ONE; BETHANECHOL; CARBAMIC ACID; CHOLINESTERASE INHIBITOR; DISTIGMINE BROMIDE; TAK 802; UNCLASSIFIED DRUG; ZANEPEZIL;

ANIMAL EXPERIMENT; ARTICLE; BLADDER CONTRACTION; BLADDER PRESSURE; CONTROLLED STUDY; DETRUSOR DYSSYNERGIA; DRUG ACTIVITY; DRUG INHIBITION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; EXAMINATION; GUINEA PIG; IC 50; MALE; MICTURITION DISORDER; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

CAVIA;

EID: 13844308650     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.01.022     Document Type: Article

References (37)

1. S.J. Berry, D.S. Coffey, P.C. Walsh, and L.L. Ewing J. Urol. 132 1984 474
2. A.C. Dinko Urology 8 1976 455
3. J.A. King, H. Huddart, and W.G. Staff Gen. Pharmacol. 30 1998 131
4. P.D. O'Donnell, and W.H. Hawkins Urology 41 1993 452
5. Schmid, O. U.S. Patent 2,789,981
6. E. Herzfeld, O. Kraupp, K. Pateisky, and Ch. Stumpf Wien. Klin. Wochenschr. 69 1957 245
7. K. Takagi, I. Takayanagi, T. Aoyama, and T. Kudo Oyo Yakuri 4 1970 741
8. Y. Tanaka, N. Masumori, N. Itoh, S. Furuya, O. Nishizawa, and T. Tsukamoto Urology 57 2001 270
9. P.J. Shah, P.H. Abrams, R.G. Choa, M.H. Ashken, C.G. Gaches, N.A. Green, and A. Wiles Brit. J. Urol. 55 1983 229
10. N.H. Philip, and D.G. Thomas Brit. J. Urol. 52 1980 942
11. A. Hameed, and T.J. Charles Brit. J. Clin. Pract. 48 1994 103
12. B. von Heyden, R.K. Riemer, L. Nunes, G.B. Brock, T.F. Lue, and E.A. Tanagho Neurourol. Urodyn. 14 1995 153
13. R. Zwart, R.G. Van Kleef, and H.P. Vijverberg Ann. NY. Acad. Sci. 868 1999 636
14. J.J. Sung, S.J. Kim, H.B. Lee, J.M. Chung, Y.M. Choi, C.I. Cha, Y.H. Suh, and K.W. Lee Muscle Nerve 21 1998 1135
15. E.F. Pereira, M. Alkoncon, T. Tano, N.G. Castro, M.M. Froes-Ferrao, R. Rozental, R.S. Aronstam, A. Schrattenholz, and A. Maelicke J. Receptor Res. 13 1993 413
16. A.E. Finkbeiner, N.K. Bissada, and L.T. Welch Urology 10 1977 83
17. Y. Ishihara, G. Goto, and M. Miyamoto Curr. Med. Chem. 7 2000 341 references are cited therein
18. Y. Ishihara, K. Hirai, M. Miyamoto, and G. Goto J. Med. Chem. 37 1994 2292
19. Y. Yamamoto, Y. Ishihara, and I.D. Kuntz J. Med. Chem. 37 1994 3141
20. Y. Ishihara, T. Tanaka, S. Miwatashi, A. Fujishima, and G. Goto J. Chem. Soc., Perkin Trans. 1 1994 2993
21. Anton, M.; Kurt, S.; Ernst-Otto, R.; Richard, R. DE2016136
22. para-Nitrobenzyloxycarbonyl group is sufficiently stable toward electrophilic species such as acyl cations, owing to the electron-withdrawing nitro group, and is easily removed by catalytic hydrogenation. Thus, the selective deprotection is feasible without effecting the protecting groups of the heterocyclic moieties (i.e., N-acetyl, N-formyl, and N-trifluoroacetyl groups)
23. G.L. Grunewald, V.H. Dahanukar, P. Ching, and K.R. Criscione J. Med. Chem. 39 1996 3539
24. A.I. Meyers, and R.H. Hutchings Tetrahedron 49 1993 1807
25. O.O. Orazi, R.A. Corral, and H. Giaccio J. Chem. Soc., Perkin Trans. 1986 1977
26. D. Evans, and I.M. Lockhart J. Chem. Soc. 1965 4806
27. P. Ruggli, B.B. Bussemaker, W. Müller, and A. Staub Helv. Chim. Acta 1935 1388
28. T. Kato, T. Niitsuma, and K. Maeda Chem. Pharm. Bull. 19 1971 832
29. G. Hallas, and D.C. Taylor J. Chem. Soc. 1964 1518
30. P.A.S. Smith, and T.-Y. Yu J. Am. Chem. Soc. 74 1952 1096
31. Zhang, S.; Hodgetts, K.; Rachwal, S.; Rosewater, D.; Thurkauf, A. WO2000-077004
32. Y. Ishihara, M. Miyamoto, T. Nakayama, and G. Goto Chem. Pharm. Bull. 41 1993 529
33. G.L. Ellman, K.D. Courtney, V. Andres, and R.M. Featherstone Biochem. Pharmacol. 7 1961 88
34. Significant difference was shown when the AUC was doubled or more, so the AUC200 value was adopted as an in vivo parameter. Also see Ref. 16
35. Intraduodenal administration was adopted instead of po administration, since animals required to be anesthetized during the rhythmic bladder contraction study
36. The reason why distigmine showed better AUC200 value than its AChE inhibition activity is not clear, but the contributions of distribution or metabolic factors are speculated
37. H. Nagabukuro, S. Okanishi, S. Imai, Y. Ishichi, Y. Ishihara, and T. Doi Eur. J. Pharmacol. 485 2004 299